biologic

Tresiba

insulin degludec

Loss of exclusivityNovember 2030projected — 12-year biologic exclusivity estimate
CompanyNovo Nordisk Inc.

Drug detail

Brand nameTresiba
Active ingredientinsulin degludec
Strength1,000UNITS/10ML (100UNITS/ML)
Dosage formInjection
RouteSubcutaneous
ModalityBiologic
FDA approvalNovember 2018
Marketing statusRx

Source: FDA Purple Book, layered on the CliffBio company graph. Cliff dates are the projected — 12-year biologic exclusivity estimate; estimates are projections, not legal advice.

Tresiba patent cliff — loss of exclusivity November 2030 | CliffBio